Literature DB >> 2547941

SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.

E J Sybertz1, P J Chiu, S Vemulapalli, B Pitts, C J Foster, R W Watkins, A Barnett, M F Haslanger.   

Abstract

SCH 39370 (N-[N-[1-(S)-carboxyl-3-phenylpropyl]-(S)-phenyl-alanyl]-(S)-isoserin e) is a potent and specific inhibitor of neutral metalloendopeptidase (NEP) from rabbit kidney (IC50 = 11.2 +/- 1.9 nM) and is devoid of angiotensin-converting enzyme inhibitory activity at 1 microM. We evaluated the effect of NEP inhibition with SCH 39370 on the inactivation of atrial natriuretic factor (ANF) and on cardiovascular function in rats. SCH 39370 effectively prevented in vitro degradation of ANF (99-126) by a purified rabbit kidney NEP. SCH 39370 (30 mg/kg s.c) significantly delayed the disappearance of immunoreactive (ir) ANF from plasma in rats after an i.v. infusion of ANF (1 microgram/kg/min for 30 min): the plasma ir ANF level at 15 min postinfusion was 1.5 +/- 0.3 ng/ml vs. 0.3 +/- 0.04 ng/ml in the control. SCH 39370 also delayed the disappearance of ir ANF after infusion of the peptide (0.1 microgram/kg/min for 30 min) which increased plasma levels to those observed during volume expansion. This effect was accentuated markedly in rats with bilateral nephrectomy. The hypotensive response to injection of ANF (30 micrograms/kg i.v.) in spontaneously hypertensive rats (-38 +/- 6 mm Hg vs. -13 +/- 2 mm Hg in the control) and the diuretic and natriuretic responses to ANF in normal rats were potentiated by SCH 39370 (30 mg/kg s.c.), respectively. The results suggest that NEP can play a role in ANF disposition in vivo and that potentiation of the biological activities of high doses of ANF by SCH 39370 may be consequent to its inhibitory effect on ANF degradation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547941

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 2.  Neprilysin Inhibitors in Cardiovascular Disease.

Authors:  Guson Kang; Dipanjan Banerjee
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

3.  Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.

Authors:  F Tomoda; R A Lew; A I Smith; A C Madden; R G Evans
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide.

Authors:  J Peyroux; F Beslot; N Claperon; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

5.  Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat.

Authors:  Y Vanneste; S Pauwels; L Lambotte; A Michel; R Dimaline; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

6.  Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo.

Authors:  R A Lew; F Tomoda; R G Evans; L Lakat; J H Boublik; L A Pipolo; A I Smith
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  In vivo measurement of ANP overall turnover and identification of its main metabolic pathways under steady state conditions in humans.

Authors:  A Clerico; G Iervasi; S Berti; A Pilo; F Vitek; S Salvadori; M Marastoni; C Manfredi; M G Del Chicca; M R Iascone
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

8.  The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.

Authors:  Srikanth Yandrapalli; Wilbert S Aronow; Pratik Mondal; David R Chabbott
Journal:  Arch Med Sci       Date:  2017-07-03       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.